Eighty percent of sexually active people get infected with HPV
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
5 sources for · 0 against
The retrieved literature indicates that the vast majority of sexually active individuals contract HPV, with reference sources citing prevalence figures around 75 to 80 percent.
Introduction Human papillomavirus (HPV) infection, a prevalent sexually transmitted disease, affects the majority of sexually active individuals at least once in their lifetime. Cervical cancer stands as a significant contributor to mortality among women. Cervical cancer screening (CCS) and HPV vaccination are recent, with few studies about their impact on the prevalence of HPV types. The emergence of novel predominant pathogen strains can be driven by vaccine-induced pathogen strain replacement, thereby enhancing and altering selection. Objective The aim of the study was to characterize the high-risk (HR) HPV infection in two Portuguese primary care units (PCUs). Materials and methods In this observational, cross-sectional, and descriptive study, we included women aged 25-64 years and registered in two PCUs, who were screened by SiiMA Rastreios (population-based screening management application), and were HR-HPV positive, between August 2015 and May 2018. The results of cervical cancer screening (CCS) can be accessed through the SiiMA Rastreios information system. For data treatment, we used MS Excel (Microsoft Corporation, Redmond, Washington, USA), IBM SPSS Statistics for Windows, Version 20 (Released 2011; IBM Corp., Armonk, New York, USA), and non-parametric tests. Results In our study, we included 4,614 women aged between 25 and 64 years old. CCS was performed on 24.47%, of whom 39.95% were tested for HR-HPV. The infection rate was 18.85%, and all 14 types of infection were identified. The most common HPV type was 31, followed by 16 and 68. We found HPV other than 16/18 in 84.43%. We found coinfections in 34.1%, with no statistically significant difference by age group. In the 25-34 age group, the incidence of infection was 33.7% vs. 17.54% in the 35-54 age group and 4.55% in the 55-64 age group. HPV16 was the most common infection in the 25-34 age group. In nulliparous women, the most common was HPV31. The relationship between smoking habits and HR-HPV infection was statistically significant, but economic insufficiency was not. Conclusion The infection incidence in this study was slightly higher than in the 2011 national study. Statistically, the infection rate was significantly higher in the younger age groups. The most frequent type varied from the national and international study results. This may be due to regional differences in HPV infection, changes in the pattern of incidence, or the effect of vaccination. The HPV pattern may be changing, so the scientific community must keep updated to develop increasingly efficient screening and vaccination programs.
Abstract
To determine the prevalence of high-risk HPV infection before first vaginal intercourse and after initiation of sexual activity in 14-22 years old girls, to find which HPV types occur most commonly. During the gynecologic exam cervical swabs were collected. Specimens were tested using Hybrid Capture 2 DNA test. In positive samples digene HPV genotyping test was performed. Subjects included 264 women, of whom 169 (64.0%) reported previous sexual activity and 95 (36.0%) had not yet had vaginal intercourse. There were 43 cases (16.3%) of high risk HPV, with 39 cases in those reporting sexual activity and 4 in virgins. Single strain HPV infection was detected in 62.8%, two strains in 23.2%, and three strains in 14.0% of subjects. HPV-16 was the most common type (20.9%), next more prevalent types were 18, 56, 31, 33 and 59. HPV-16 or HPV-18 were detected in 39.5% of the subjects. Not a single case was identified containing both types. The prevalence of high-risk HPV is common in sexually active young Lithuanian women. HPV were found in a small percentage of girls who had never had vaginal intercourse. The prevalence of types 16 and 18 among Lithuanian women was higher than in international data.
What is HPV? Human papillomavirus (HPV) is a group of more than 200 related viruses. Some of them are spread through sexual contact. Most people have been exposed to HPV. Usually, your immune system controls HPV infections, and they go away on their own and don't cause any health problems, but some need treatment. There are two categories of sexually transmitted HPV. They are called low-risk HPV and high-risk HPV. Sometimes high-risk HPV infections can stay at the cervix (the lower part of a woman's uterus) for many years. This can lead to cell changes. If these changes are not screened for and treated, they may get worse over time and become cancer. Low-risk HPVM can cause warts on or around your genitals, anus, mouth, or throat. High-risk HPV can cause various cancers: Cervical cancer Anal cancer Oropharyngeal cancer, a type of head and neck cancer, also called throat cancer Vulvar cancer Vaginal cancer Penile cancer Who is at risk for HPV infections? HPV infections are very common. Nearly all sexually active people are infected with HPV soon after they become sexually active. What are the symptoms of HPV infections?
We report the rationale, design, methods and details of participation of a community-based, double-blind, randomized clinical trial of an HPV 16 and 18 vaccine conducted in two provinces of Costa Rica to investigate the efficacy and population impact of the vaccine in the prevention of cervical cancer precursors. More than 24,000 women between 18 and 25 years of age were invited to participate and pre-screened for eligibility, with recruitment of 7466 women (30% of those pre-screened, 59% of those eligible) who were randomized to receive 3 doses of the HPV vaccine or hepatitis A vaccine as control. A complex protocol of data and specimen collection was applied, including an interview, pelvic exam for sexually active women, blood for serology and cell-mediated immunity, cervical secretions for local immunity and cells for HPV, Chlamydia trachomatis and gonorrhea testing. Eighty percent of the women received three doses, 12.4% two doses and 7.4% one dose. At visits, compliance with data and specimen collection was close to 100%. Baseline characteristics and age-specific prevalence of HPV and cervical neoplasia are reported. Overall prevalence of HPV was high (50%), with 8.3% of women having HPV 16 and 3.2% HPV 18. LSIL was detected in 12.7% of women at baseline and HSIL in 1.9%. Prevalence of Chlamydia was 14.2%. There was very good agreement in HPV detection between clinician-collected and self- collected specimens (89.4% agreement for all types, kappa 0.59). Follow up will co
66% of sexually experienced females and 71% of males. • Nearly all sexually active females … (38%) of both sexually active teens and those who are not sexually active agree that when … transmitted diseases. • About 75 percent of sexually active people will get HPV sometime in
Everything we examined (5)
This check searched the claim as stated. It did not run a separate search for evidence against it.